@drj1189: Mounjaro has a new FDA indication—and this one is worth understanding beyond the headline. The FDA has expanded Mounjaro’s indication to include reducing the risk of major adverse cardiovascular events—cardiovascular death, heart attack, or stroke—in adults with type 2 diabetes who are at high cardiovascular risk. This matters because when we treat type 2 diabetes, we’re not just thinking about A1C or the number on the scale. Cardiovascular disease remains one of the biggest concerns for these patients, so medications that can address multiple parts of that risk are clinically important. One important nuance: this does not mean Mounjaro is now a cardiovascular-risk medication for everyone taking it, or that every person with obesity should be prescribed it for heart protection. The new indication applies specifically to adults with type 2 diabetes who are at high risk for cardiovascular events. It’s another example of why these medications have moved well beyond the conversation of simply being “weight-loss drugs.” Talk with your physician about what your individual cardiovascular risk looks like and which treatments make sense for you. For medical education only; not individualized medical advice. #Mounjaro #Tirzepatide #Type2Diabetes #CardiovascularHealth #DiabetesCare

Dr. J

Open In TikTok:

Region: US

Friday 04 September 2026 23:34:47 GMT